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Abstract
Objective: Serum uric acid (SUA) is a cardiovascular risk marker associated with inflammation. The serum amyloid A protein
(SAA) is an inflammatory factor and is associated with cardiovascular disease (CVD). However, the relationship between
genetic polymorphisms of SAA and SUA levels has not been studied. The objective of this study was to investigate the
association between SUA levels and SAA genetic polymorphisms.
Methods: All participants were selected from subjects participating in the Cardiovascular Risk Survey (CRS) study. The single
nucleotide polymorphism (SNP) rs12218 of the SAA1 gene was genotyped by using the polymerase chain reaction–
restriction fragment length polymorphism (PCR-RFLP) method. The association of SUA levels with genotypes was assessed
by using the general liner mode.
Results: The SNP rs12218 was associated with SUA levels by analyses of a dominate model (P=0.002) and additive model
(P=0.005), and the difference remained significant after adjustment of sex, age, obesity, ethnicity, HDL-C, alcohol intake,
smoking, and creatinine (P=0.006 and P=0.023, respectively). The TT genotype was associated with an increased SUA
concentration of 39.34 mmol/L (95% confidence interval [CI], 3.61–75.06, P=0.031) compared with the CC genotype, and
the TT genotype was associated with an increased SUA concentration of 2.48 mmol/L (95% CI, 6.86–38.10; P=0.005)
compared with the CT genotype.
Conclusions: The rs12218 SNP in the SAA1 gene was associated with SUA levels in Chinese subjects, indicating that carriers
of the T allele of rs12218 have a high risk of hyperuricemia.
Citation: Xie X, Ma Y-T, Yang Y-N, Li X-M, Fu Z-Y, et al. (2012) Serum Uric Acid Levels Are Associated with Polymorphism in the SAA1 Gene in Chinese
Subjects. PLoS ONE 7(6): e40263. doi:10.1371/journal.pone.0040263
Editor: Weijing He, University of Texas Health Science Center San Antonio Texas, United States of America
Received January 20, 2012; Accepted June 6, 2012; Published June 29, 2012
Copyright:  2012 Xie et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Encouraged Fund for Research of Xinjiang Medical University (2010YFY08) on the basis of the National Natural Science Foundation of China (81160017)
and Natural Science Foundation of Xinjiang (2011211D32). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: myt-xj@163.com
Introduction
Serum uric acid (SUA) is the final product of purine metabolism
in humans and higher primates. It has a well-established role in
gout and is associated with other forms of inflammation and
immune regulation as well [1]. The results of recent studies suggest
that hyperuricemia is associated with inflammation [2,3]. A high
level of SUA is associated with hypertension [4,5], insulin
resistance [6,7], obesity [6,8] and cardiovascular events [5,9]. A
potential mechanism by which uric acid could be associated with
cardiovascular morbidity is via inflammation [10]. Experimental
results show that SUA can stimulate the release of C-reactive
protein (CRP) when entering vascular smooth muscle cells [11–
12].
Serum amyloid A (SAA), one of the acute phase proteins, is an
important inflammatory factor. The results of a previous study
[13] show that in vivo concentrations of SAA can be dramatically
increased (up to 1000-fold) in plasma during acute inflammatory
conditions [14]. However, the relationship between SUA and SAA
is unknown. In previous studies, we observed that the single
nucleotide polymorphism (SNP) rs12218 in the SAA1 gene was
associated with increased carotid artery intima – media thickness
(IMT) values [15] and decreased HDL-C levels [16] and Ankle-to-
Brachial Index [17], which are considered to be risk factors for
cardiovascular disease (CVD). SUA levels were also associated
with the risk of CVD via inflammation [10]. And SAA has been
reported to be a more sensitive marker of inflammation and CVD
than C-reactive protein (CRP) [13,14]. Therefore, we hypothe-
sized that rs12218 of SAA1 is associated with SUA levels.
Methods
This study was approved by the Ethics Committee of the First
Affiliated Hospital of Xinjiang Medical University and was
conducted according to the standards of the Declaration of
Helsinki. Written, informed consent was obtained from the
participants.
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All the participants were selected from the Cardiovascular Risk
Survey (CRS) study, which was described previously [15,17].
Briefly, the CRS included 14 618 participants (5 757 Hans, 4 767
Uygurs, and 4 094 Kazakhs). Of these 14 618 subjects, 1078
participants who were free from CVD were initially screened for
the present study. The exclusion criteria were as follows: systolic
and diastolic blood pressure (BP) $140/90 mmHg; fasting plasma
glucose .7.0 mmol/L; total cholesterol .7.8 mmol/L; triglycer-
ides .2.0 mmol/L; or electrocardiography (ECG) abnormalities
and carotid artery plaques. Of the 1078 screened, 107 were
excluded, leaving us with 971 subjects for the present study.
Among these 971 subjects, only 568 consented to providing blood
samples for DNA analysis. The analysis presented in the present
study was based on these 568 participants who met the eligibility
criteria and for whom complete SAA1 genotype data were
available.
Biological and lifestyle measurements
Height and body weight were measured as described previously
[18]. Sitting blood pressure was measured three times during
10 min, and the median value was used for statistical analysis.
Smoking and drinking status was self-reported via the study
questionnaire as described previously [19,20]. Body mass index
(BMI) was calculated by dividing the weight in kilograms by the
height in meters squared. Obesity was defined as BMI $25 kg/m2
which was based on the WHO Asia-Pacific Area criterion for
obesity described previously [18]. We measured the serum
concentration of uric acid, total cholesterol, triglyceride, blood
urea nitrogen (BUN), creatinine (Cr), low density lipoprotein
(LDL), high density lipoprotein (HDL), and fasting glucose using
chemical analysis equipment (Dimension AR/AVL Clinical
Chemistry System, Newark, NJ) in the Clinical Laboratory
Department of the First Affiliated Hospital of Xinjiang Medical
University as described previously [15–17,19,20].
SAA1 SNP genotyping
As described in the previous study [17], there are 115 SNPs for
the human SAA 1 gene listed in the National Center for
Biotechnology Information SNP database (http://www.ncbi.nlm.
nih.gov/ SNP). Using the Haploview 4.2 software and the
HapMap phrase II database, we obtained four tagging SNPs
(rs12218, rs4638289, rs7131332 and rs11603089) for Chinese
Hans by using minor allele frequency (MAF) $0.05 and linkage
disequilibrium patterns, with r
2$0.8 as a cutoff. Because we
found that only rs12218 was associated with CVD risks in the
previous studies [15–17], we selected rs12218 for the present
study. We genotyped rs12218 according to the protocol described
previously [17]. To ensure the results were verified, 10% of the
genotyped samples were duplicated, and at least one positive and
one negative control per 96-well DNA plate were used in our
assays. The accuracy of the genotyping was determined by
assessing the genotype concordance between duplicate samples.
We obtained a 100% concordance between the genotyped
duplicate samples for the SNP. The genotyping success rate was
100%.
Table 1. Demographic and Risk Profile of the Study Population.
Risk factor No. (%) or Mean (SD)
Total cohort (n=658) Men (n=450) Women (n=118)
Age (years) 57.24 (11.84) 57.18 (12.28) 57.46 (10.01)
Obesity 150 (26.40) 124 (27.56) 26 (22.03)
Never drink (%) 312(54.9) 237 (52.7) 75 (63.6)
Former drinker (%) 154(27.1) 114 (25.3) 40 (33.9)
Current drinker (%) 102(18.0) 99 (22.0) 3 (2.5)
Never smoking (%) 213 (37.5) 136 (30.2) 77 (65.3)
Former smoking (%) 153 (26.9) 114 (25.3) 39 (33.1)
Current smoking (%) 202 (35.6) 200 (44.4) 2 (1.7)
BUN (mmol/L) 5.16 (1.53) 5.27 (1.56) 4.76 (1.36)
Cr (mmol/L) 75.29 (19.96) 78.91 (20.03) 61.49 (12.21)
Uric acid (mmol/L) 321.32(92.68) 336.18 (93.63) 264.68 (62.46)
Glucose (mmol/L) 4.69 (0.82) 4.67 (0.85) 4.75 (0.68)
Triglyceride (mmol/L) 1.81 (1.39) 1.86 (1.43) 1.65 (1.23)
Total cholesterol (mmol/L) 4.58 (1.16) 4.58 (1.18) 4.61(1.10)
HDL –C (mmol/L) 1.40 (0.46) 1.39 (0.47) 1.45 (0.39)
LDL-C (mmol/L) 3.06(1.0) 3.06 (0.98) 3.09 (1.07)
Note: HDL, high-density lipoprotein; LDL, high-density lipoprotein;
doi:10.1371/journal.pone.0040263.t001
Table 2. Distribution of rs12218 in Han, Uygur, and Kazak
population.
Rs12218 Ethnicity P value
Han
(n=321)
Uygur
(n=115)
Kazak
(n=132)
CC, n (%) 19 (5.92) 1 (0.87) 8 (6.06) 0.012
CT, n (%) 124 (38.63) 64 (55.65) 57 (43.18)
TT, n (%) 178 (55.45) 50 (43.48) 67 (50.76)
doi:10.1371/journal.pone.0040263.t002
SAA1 Gene and SUA
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e40263Statistical analysis
All analyses were performed by using SPSS version 17.0 (SPSS,
Chicago, IL, USA). Hardy-Weinberg equilibrium was assessed by
chi-square analysis. Serum UA levels were normally distributed;
therefore, the original values were used for analysis. General linear
model (GLM) analysis was performed to test for associations
between SNP genotypes and serum UA after adjusting for
confounding variables. Two-tailed P-values were considered to
be significant at the 0.05 level.
Results
Characteristics of study participants
The study cohort consisted of 568 subjects (450 men, 118
women). The clinical and metabolic characteristics of the study
population are shown in Table 1. Table 2 shows the distributions
of rs12218 in the Han, Uygur, and Kazak populations. Genotype
distributions between each ethnicity were significantly different
(P=0.012). Table 3 shows the characteristics of study participants
according to their rs12218 genotypes. Each genotype was
significantly different in terms of SUA, HDL-C, and drinking
behavior (P,0.05 for all comparisons).
Table 3. Demographic and Risk Profile of the Study Population According to rs12218 Genotypes.
Risk factor rs12218 genotypes [No. (%) or Mean (SD)] p
CC (n=28) CT (n=245) TT (n=295)
Age (years) 56.43(12.07) 58.47(11.77 56.3(11.82 0.100.
Obesity 8 (28.57) 67 (27.35) 75 (25.42) 0.850
Never drink (%) 12 (42.86) 147 (60.0) 153 (51.86) 0.004
Former drinker (%) 15 (53.57) 56 (22.86) 83 (28.13)
Current drinker (%) 1 (3.57) 42 (17.14) 59 (20.0)
Never smoking (%) 10 (35.71) 101 (41.22) 102 (34.58) 0.557
Former smoking (%) 8 (28.57) 59 (24.08) 86 (29.15)
Current smoking (%) 10 (35.71) 85 (34.69) 107 (36.27)
BUN (mmol/L) 5.02(1.44) 5.22(1.67) 5.13(1.40) 0.709
Cr (mmol/L) 70.94(23.3) 74.21(18.95) 76.6(20.40) 0.191
Uric acid (mmol/L) 293.62(92.89) 310.48(89.8) 332.96(93.68) 0.005
Glucose (mmol/L) 4.69(0.64) 4.72(0.83) 4.65(0.81) 0.675
Triglyceride (mmol/L) 1.63(0.85) 1.79(1.43) 1.85(1.39) 0.683
Total cholesterol (mmol/L) 4.47(1.17) 4.62(1.28) 4.56(1.04) 0.710
HDL –C (mmol/L) 1.26(0.40) 1.41(0.49) 1.47(0.42) 0.042
LDL-C (mmol/L) 3.24(1.23) 3.05(1.03) 3.05(0.94) 0.619
Note: HDL, high-density lipoprotein; LDL, high-density lipoprotein;
doi:10.1371/journal.pone.0040263.t003
Table 4. SUA levels and SAA1 genotypes.
SNP Unadjusted model Adjusted model1
rs12218 Genotypes SUA (mmol/L) Mean (SD) P value SUA (mmol/L) Mean (SE) P value
Additive model
CC (n=28) 293.62 (92.89) 0.005 309.72 (15.25) 0.023
CT (n=245) 310.48 (89.80) 312.10 (5.15)
TT (n=295) 332.96 (93.68) 330.49 (4.68)
Dominant model
CC+CT (n=273) 308.75 (90.09) 0.002 311.86 (4.87) 0.006
TT (n=295) 332.96 (93.68) 330.49 (4.68)
Recessive model
CC (n=28) 293.62 (92.89) 0.105 309.88 (15.33) 0.436
CT+TT (n=540) 322.76 (92.53) 322.16 (3.47)
1Analysis of covariance adjusted for sex, age, Cr, obesity, ethnicity, HDL-C, smoking and drinking.
doi:10.1371/journal.pone.0040263.t004
SAA1 Gene and SUA
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The genotype frequencies for the rs12218 were in Hardy-
Weinberg equilibrium (P.0.05). Table 4 shows that rs12218 was
associated with SUA levels by analyses of a dominate model
(P=0.002) and an additive model (P=0.005), and the difference
remained significant after adjustment for sex, age, ethnicity, HDL-
C, obesity, alcohol intake, smoking, and creatinine levels
(P=0.006, P=0.023, respectively). The TT genotype was
associated with an increased SUA concentration of 39.34 mmol/
L (95% confidence interval [CI], 3.61–75.06, P=0.031) compared
with the CC genotype, and the TT genotype was associated with
an increased SUA concentration of 2.48 mmol/L (95% CI, 6.86–
38.10; P=0.005) compared with the CT genotype. Taking into
account the possible interactions between rs12218 and other
variables, we analyzed all these variables using a general linear
model and found no interactions between rs12218 and sex, alcohol
intake, or HDL-C level (Table 5).
Discussion
In the present study, we observed that variation in the SAA1
gene is associated with SUA in Chinese subjects. Individuals with
the T allele of rs12218 had significantly higher SUA levels than
did C allele carriers. To the best of our knowledge, this is the first
study to investigate the common allelic variant in the SAA1 gene
and its association with SUA levels.
Hyperuricemia has been implicated in multiple physiologic
outcomes, including coronary artery disease, hypertension [4,5],
and obesity [6,8]. Hyperuricemia is suspected to influence the
development of CVD via its role in inflammation [10]. SAA is in a
family of proteins that forms a major component of the acute-
phase inflammatory response [21]. It is synthesized in the liver in
response to inflammation and infection [22] and is considered to
be a sensitive marker of an acute inflammatory state. Therefore,
SUA and SAA may be associated. However, up to date, the
relationship between SAA and SUA remains unclear.
Accumulated evidence generated from genome-wide association
studies (GWAS) has linked uric acid to specific genomic loci, such
as SLC2A9, PDZK1, GCKR, SLC16A9, SLC22A11, SLC22A12,
and ABCG2, in individuals of European and Asian descent [23–
26]. Although the foundation for human studies examining
putative causative genes that may be involved in hyperuricemia
is based on a GWAS method, the candidate-gene approach is an
important way to explore the association of hyperuricemia with
genetic polymorphisms. This approach involves selecting a
functionally relevant gene to study and subsequently investigating
its association with SUA levels. The gene for SAA1 is a candidate
hyperuricemia gene because it encodes the important inflamma-
tion factor SAA. This factor was identified in the early 1970s as the
plasma protein responsible for forming tissue deposits called
amyloid (AA-type), which are seen clinically in diseases with
underlying persistent acute inflammation [27,28].
In previous studies, we found that the rs12218 SNP in the SAA1
gene was associated with IMT [15], HDL level [16], and ABI [17],
which is involved in CVD. In the present study, we found that the
rs12218 polymorphism is associated with SUA concentration,
which is also related to CVD. Compared with C-allele carriers,
individuals with the T allele of rs12218 had significantly higher
SUA levels. This association remains significant after adjustment
for sex, age, obesity, ethnicity, HDL-C, alcohol intake, smoking
status, and creatinine levels.
The mechanisms which may link SAA1 genetic polymorphisms
to SUA levels are largely unknown. The results of previous studies
show a close association between elevated SUA and several
inflammatory markers such as white blood cells, TNF-a, and CRP
[29]. Also, uric acid directly stimulates the production of
inflammatory mediators such as CRP in vascular cells [30].
However, the relationship between SAA and SUA remains
unclear. In the present study, we observed that the SAA1 genetic
polymorphism was associated with elevated SUA after adjusting
for other confounders, indicating that the SAA1 gene polymor-
phism may be independently related to SUA level. However, the
relationship between rs12218 and SUA may simply reflect their
association with other inflammatory factors. Therefore, functional
studies of rs12218 should be performed in the future.
In addition, rs12218 is a synonymous mutation and does not
result in amino acid changes in the protein. However, rs12218
acting as a tagging SNP of SAA1 gene may be in total linkage
disequilibrium with a nonsynonymous mutation, which we did not
examine. Because both SAA and SUA are related to inflamma-
tion, the association of SAA1 polymorphism with SUA may be
linked to SAA levels. In 1999, Yama et al. [31] reported that the
SAA1 allele influences the plasma concentration of SAA. In the
Japanese population, subjects with the SAA1.5 allele have a higher
plasma concentration of SAA than those lacking this allele. In the
present study, we did not examine the differences in SAA levels
between each genotype, which was a limitation of our analysis. We
think that this SNP may be associated with rs12218 although we
could not identify the rs number of the SAA1.5 polymorphism
described by Yama et al [29]. Dietary intake of certain
macronutrients and food items may also significantly affect SUA
concentration. However, because of the absence of these data in
our database, we did not include these factors in our multivariable
analysis, which is also a limitation of our study. We also did not
perform experiments related to SAA1 gene function. In addition, in
the present study, we found that there was significantly difference
in distributions of genotypes in Han, Uygur, and Kazak
population. However, due to the very small sample size in Uygur
Table 5. Interaction of rs12218 and other confounders on
SUA.
Source Squares df
Mean
Square F P
Corrected Model 1.801610
26 19 94787.509 17.145 ,0.001
Rs12218 14194.811 2 7097.406 3.155 0.043
Age 27856.254 1 27856.254 5.039 0.025
BUN 27943.440 1 27943.440 5.054 0.025
Glucose 7013.364 1 7013.364 1.269 0.261
Cr 403270.745 1 403270.745 72.944 ,0.001
Triglyceride 201494.695 1 201494.695 36.446 ,0.001
Total cholesterol 1215.210 1 1215.210 0.220 0.639
HDL-C 4810.028 1 4810.028 0.870 0.351
LDL-C 64303.867 1 64303.867 11.631 0.001
Sex 91370.100 1 91370.100 16.527 ,0.001
Drinking 1869.215 1 1869.215 0.338 0.561
Obesity 42965.305 1 42965.305 7.772 0.005
Rs12218 * sex 11572.711 2 5786.355 1.047 0.352
Rs12218 * drinking 8397.275 2 4198.638 0.759 0.468
Rs12218* HDL-C 693.427 2 346.713 0.063 0.939
R Squared=0.374 (Adjusted R Squared=0.352).
doi:10.1371/journal.pone.0040263.t005
SAA1 Gene and SUA
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between rs12218 and SUA in each ethnicity. Alternatively, we
pooled these three ethnicities together to analyze the data and
adjusted the effect of ethnicity by using multivariable analysis. This
may be another limitation in our research.
In conclusion, a polymorphism of SAA1 gene was associated
with the SUA level in Chinese subjects; our observation requires
replication in a different population.
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